Multiple E. coli cultivations, producing recombinant proteins, lead to the formation of inclusion bodies (IBs). IBs historically were considered as nondesired by-products, due to their time- and cost-intensive purification. Nowadays, many obstacles in IB processing can be overcome. As a consequence, several industrial processes with E. coli favor IB formation over soluble production options due to the high space time yields obtained. Within this chapter, we discuss the state-of-the art biopharmaceutical IB process, review its challenges, highlight the recent developments and perspectives, and also propose alternative solutions, compared to the state-of-the art processing.
CITATION STYLE
Kopp, J., & Spadiut, O. (2023). Inclusion Bodies: Status Quo and Perspectives. Methods in Molecular Biology (Clifton, N.J.), 2617, 1–13. https://doi.org/10.1007/978-1-0716-2930-7_1
Mendeley helps you to discover research relevant for your work.